Nanjing Olimex Medical Technology Co., Ltd. was established in 2017. The company's strategy is to follow up quickly, that is, to select targets that have completed clinical proof-of-concept as "me-too" drugs, which can greatly reduce the risk of research and development. The field currently selected is mainly cancer, and the research and development follow the international mainstream anti-tumor drug research and development direction.